MicroPort CardioFlow Medtech Balance Sheet Health
Financial Health criteria checks 5/6
MicroPort CardioFlow Medtech has a total shareholder equity of CN¥2.3B and total debt of CN¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CN¥2.6B and CN¥242.2M respectively.
Key information
0%
Debt to equity ratio
CN¥0
Debt
Interest coverage ratio | n/a |
Cash | CN¥1.78b |
Equity | CN¥2.33b |
Total liabilities | CN¥242.25m |
Total assets | CN¥2.58b |
Recent financial health updates
MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans
May 29We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth
Feb 23Companies Like MicroPort CardioFlow Medtech (HKG:2160) Are In A Position To Invest In Growth
Oct 04We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth
May 23MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans
Feb 08We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth
Oct 18Recent updates
Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 43%?
Aug 07Some MicroPort CardioFlow Medtech Corporation (HKG:2160) Shareholders Look For Exit As Shares Take 26% Pounding
Jun 19MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans
May 29MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely
Apr 05We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth
Feb 23An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 37% Undervalued
Jan 18Companies Like MicroPort CardioFlow Medtech (HKG:2160) Are In A Position To Invest In Growth
Oct 04Not Many Are Piling Into MicroPort CardioFlow Medtech Corporation (HKG:2160) Stock Yet As It Plummets 27%
May 31We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth
May 23The MicroPort CardioFlow Medtech Corporation (HKG:2160) Analysts Have Been Trimming Their Sales Forecasts
Apr 06MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans
Feb 08We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth
Oct 18We're Not Very Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn Rate
Jun 30Analysts Just Made A Major Revision To Their MicroPort CardioFlow Medtech Corporation (HKG:2160) Revenue Forecasts
Apr 04MicroPort CardioFlow Medtech Corporation (HKG:2160) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Apr 03An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 49% Undervalued
Jan 21Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 24%?
Sep 05We're Not Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn
Jun 07Market Sentiment Around Loss-Making MicroPort CardioFlow Medtech Corporation (HKG:2160)
May 03Financial Position Analysis
Short Term Liabilities: 2160's short term assets (CN¥2.0B) exceed its short term liabilities (CN¥193.6M).
Long Term Liabilities: 2160's short term assets (CN¥2.0B) exceed its long term liabilities (CN¥48.7M).
Debt to Equity History and Analysis
Debt Level: 2160 is debt free.
Reducing Debt: 2160 has no debt compared to 5 years ago when its debt to equity ratio was 27.9%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2160 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 2160 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.